TY - JOUR
T1 - Pharmacological secondary prevention in patients with mesenterial artery atherosclerosis and arterial embolism
AU - Gottsäter, Anders
PY - 2017
Y1 - 2017
N2 - Visceral arteries such as the coeliac (CA), superior mesenteric (SMA), and the inferior mesenteric artery (IMA) might be affected by atherosclerotic occlusive lesions with or without thrombosis or embolization causing ischaemic symptoms from the gastrointestinal tract.After treatment of an acute event, these patients should be offered both non-pharmacological and pharmacological secondary prevention to reduce risk for future ischaemic arterial manifestations. Patients with mesenteric ischaemia caused by atherosclerosis should be evaluated concerning platelet antiaggregation with low dose aspirin or clopidogrel, and those with cardioembolic disease should be recommended anticoagulant treatment with either warfarin or one of the direct oral anticoagulants (DOAC; apixaban, dabigatran, edoxaban, or rivaroxaban). In all patients, blood pressure should be lowered to <140/90 mmHg with ACE-inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, or thiazide diuretics, and LDL-cholesterol should be kept at <1.8 mmol/l, preferably with statins. If present, diabetes should be treated aiming at good metabolic control, and all smokers should be recommended cessation.
AB - Visceral arteries such as the coeliac (CA), superior mesenteric (SMA), and the inferior mesenteric artery (IMA) might be affected by atherosclerotic occlusive lesions with or without thrombosis or embolization causing ischaemic symptoms from the gastrointestinal tract.After treatment of an acute event, these patients should be offered both non-pharmacological and pharmacological secondary prevention to reduce risk for future ischaemic arterial manifestations. Patients with mesenteric ischaemia caused by atherosclerosis should be evaluated concerning platelet antiaggregation with low dose aspirin or clopidogrel, and those with cardioembolic disease should be recommended anticoagulant treatment with either warfarin or one of the direct oral anticoagulants (DOAC; apixaban, dabigatran, edoxaban, or rivaroxaban). In all patients, blood pressure should be lowered to <140/90 mmHg with ACE-inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, or thiazide diuretics, and LDL-cholesterol should be kept at <1.8 mmol/l, preferably with statins. If present, diabetes should be treated aiming at good metabolic control, and all smokers should be recommended cessation.
KW - Anticoagulation
KW - Antiplatelet treatment
KW - Atherosclerosis
KW - Blood pressure lowering
KW - Coeliac artery (CA)
KW - Embolization
KW - Inferior mesenteric artery (IMA)
KW - Lipid lowering
KW - Superior mesenteric artery (SMA)
KW - Thrombosis
UR - http://www.scopus.com/inward/record.url?scp=84999737840&partnerID=8YFLogxK
U2 - 10.1016/j.bpg.2016.07.004
DO - 10.1016/j.bpg.2016.07.004
M3 - Article
C2 - 28395781
AN - SCOPUS:84999737840
SN - 1521-6918
VL - 31
SP - 105
EP - 109
JO - Best Practice and Research in Clinical Gastroenterology
JF - Best Practice and Research in Clinical Gastroenterology
IS - 1
ER -